Peptides from the variable region of specific antibodies are shared among lung cancer patients

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  De Costa, Dominique ^a   Broodman, Ingrid ^a   Calame, Wim ^b   Stingl, Christoph ^a   Dekker, Lennard J M ^a   Vernhout, René M ^a   De Koning, Harry J ^a   Hoogsteden, Henk C ^a   Sillevis Smitt, Peter A E ^a   Van Klaveren, Rob J ^a   Luider, Theo M ^a   VanDuijn, Martijn M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b StatistiCal BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; TUMOR ANTIGEN; ANTIBODY; IMMUNOGLOBULIN VARIABLE REGION; PEPTIDE;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE SEQUENCE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; LIQUID CHROMATOGRAPHY; LUNG CANCER; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; AGED; AMINO ACID SEQUENCE; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; FEMALE; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY;

AGED; AMINO ACID SEQUENCE; ANTIBODIES; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PEPTIDES; REPRODUCIBILITY OF RESULTS;

EID: 84900445442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096029     Document Type: Article

References (39)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer.
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
4. Horeweg N, van der Aalst CM, Vliegenthart R, Zhao Y, Xie X, et al. (2013) Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J 42: 1659-1667.
5. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, et al. (2009) Management of lung nodules detected by volume CT scanning. N Engl J Med 361: 2221-2229.
6. Anderson KS, LaBaer J (2005) The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4: 1123-1133. (Pubitemid 41208670)
7. Baldwin RW (1955) Immunity to transplanted tumour: the effect of tumour extracts on the growth of homologous tumours in rats. Br J Cancer 9: 646-651.
8. Caron M, Choquet-Kastylevsky G, Joubert-Caron R (2007) Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6: 1115-1122. (Pubitemid 47099223)
9. Gure AO, Altorki NK, Stockert E, Scanlan MJ, Old LJ, et al. (1998) Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 58: 1034-1041. (Pubitemid 28182475)
10. Hanash S (2003) Harnessing immunity for cancer marker discovery. Nat Biotechnol 21: 37-38.
11. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, et al. (2003) Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21: 57-63. (Pubitemid 36055828)
12. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, et al. (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354. (Pubitemid 28189124)
13. Liu L, Liu N, Liu B, Yang Y, Zhang Q, et al. (2012) Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol.
14. Murphy KTP, Walport M (2008) Janeway's immunobiology. Garland Science.
15. Saada R, Weinberger M, Shahaf G, Mehr R (2007) Models for antigen receptor gene rearrangement: CDR3 length. Immunol Cell Biol 85: 323-332. (Pubitemid 46878931)
16. Foreman AL, Lemercier B, Lim A, Kourlisky P, Kenny T, et al. (2008) VH gene usage and CDR3 analysis of B cell receptor in the peripheral blood of patients with PBC. Autoimmunity 41: 80-86.
17. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637.
18. VanDuijn MM, Dekker LJ, Zeneyedpour L, Smitt PA, Luider TM (2010) Immune responses are characterized by specific shared immunoglobulin peptides that can be detected by proteomic techniques. J Biol Chem 285: 29247-29253.
19. Weinstein JA, Jiang N, White RA, 3rd, Fisher DS, Quake SR (2009) Highthroughput sequencing of the zebrafish antibody repertoire. Science 324: 807-810.
20. Maat P, VanDuijn M, Brouwer E, Dekker L, Zeneyedpour L, et al. (2012) Mass spectrometric detection of antigen-specific immunoglobulin peptides in paraneoplastic patient sera. J Autoimmun 38: 354-360.
21. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, et al. (2007) Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 120: 868-874. (Pubitemid 46175408)
22. de Costa D, Broodman I, Vanduijn MM, Stingl C, Dekker LJ, et al. (2010) Sequencing and quantifying IgG fragments and antigen-binding regions by mass spectrometry. J Proteome Res 9: 2937-2945.
23. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, et al. (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37: D1006-1012.
24. Snedecor GW (1980) Statistical Methods. Iowa: The Iowa State University Press.
25. Armitage P, Berry GS (2002) Statistical Methods in Medical Research. Oxford: Blackwell Scientific.
26. Afifi A, Clark V, May S (2004) Computer-aided multivariate analysis. Florida: Chapman & Hall.
27. Kleinbaum DG, Kupper LL, Muller KE, Nizam A (1998) Applied regression analysis and other multivariable methods. California: Duxbury Press.
28. Arentz G, Thurgood LA, Lindop R, Chataway TK, Gordon TP (2012) Secreted human Ro52 autoantibody proteomes express a restricted set of public clonotypes. J Autoimmun 39: 466-470.
29. Andersen PS, Haahr-Hansen M, Coljee VW, Hinnerfeldt FR, Varming K, et al. (2007) Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol Immunol 44: 412-422. (Pubitemid 44308352)
30. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, et al. (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163: 5133-5144. (Pubitemid 29501283)
31. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S (2001) Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61: 7908-7912. (Pubitemid 33049381)
32. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, et al. (2001) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98: 9824-9829. (Pubitemid 32769388)
33. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, et al. (2012) EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol.
34. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, et al. (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9: 5120-5126. (Pubitemid 37413560)
35. Khattar NH, Coe-Atkinson SP, Stromberg AJ, Jett JR, Hirschowitz EA (2010) Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer. Cancer Biol Ther 10: 267-272.
36. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, et al. (2006) Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1: 513-519. (Pubitemid 47181397)
37. Pass HI, Johnson DH, Minna JD, Scagliotti GV, Turrisi AT (2010) Principles and practice of lung cancer. The official reference text of the IASLC. Lippincott Williams & Wilkins.
38. Villeneuve PJ, Mao Y (1994) Lifetime probability of developing lung cancer, by smoking status, Canada. Can J Public Health 85: 385-388.
39. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, et al. (2012) Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev 21: 786-792.